mCRPC
mCRPC
Metastatic castration-resistant prostate cancer
Emily MenendezmCRPC | December 5, 2022
Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety.
Read More
Emily MenendezmCRPC | November 17, 2022
Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients.
Emily MenendezRLT-PSMA | November 14, 2022
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Emily MenendezRLT-PSMA | November 14, 2022
Studies have investigated the effects of 177Lu-PSMA and 225Ac-PSMA RNT in mCRPC patients, with promising treatment results.
Leah LawrencemCRPC | October 25, 2022
Olaparib with cediranib significantly improved rPFS in men with mCRPC, but was associated with an increase in adverse events.
Akhil Abraham Saji, MDJournal | October 24, 2022
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
Leah LawrencemCRPC | October 4, 2022
mCRPC patients with BRCA or ATM mutations had improved radiographic progression-free survival when treated with rucaparib.
Patrick DalyESMO 2022 | September 14, 2022
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
Patrick DalyESMO 2022 | September 14, 2022
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Patrick DalyESMO 2022 | September 14, 2022
Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.
Patrick DalyESMO 2022 | September 12, 2022
177Lu-PSMA-RLT showed efficacy and safety consistent with published evidence in cohort of very old patients with mCRPC.
Patrick DalyESMO 2022 | September 12, 2022
Karim Fizazi discussed preliminary findings on ODM-208, a first-in-class CYP11A1 inhibitor at ESMO 2022.
Patrick DalyESMO 2022 | September 10, 2022
Researchers evaluated immune effects of enzalutamide in patients with metastatic castration-resistant prostate cancer on ADT.
Patrick DalyESMO 2022 | September 10, 2022
Pembrolizumab plus olaparib did not improve survival versus alternating from abiraterone or enzalutamide in mCRPC.
Leah LawrencemCRPC | August 18, 2022
Combining an investigational bispecific antibody with a PD-1 inhibitor showed anti-tumor activity in advanced mCRPC.
Cecilia BrownmCRPC | July 26, 2022
Median OS was longer in patients who had a decrease in PSA levels than in patients who had a sustained increase.
GU Oncology Now EditorsmCRPC | June 2, 2022
Researchers evaluate the frequency of germline DDRg mutations in metastatic prostate cancer patients of different ancestries.
Advertisement
Advertisement